CatalYm today announced the presentation of the first preclinical data demonstrating that the company's clinical-stage antibody visugromab can improve the anti-tumor activity of antibody-drug ...

Agenus Inc. , a clinical-stage immuno-oncology company, today announced updated data from the hepatocellular carcinoma (HCC) cohort of its ongoing Phase 1 study evaluating botensilimab (BOT) in ...

"We are excited about the potential of BDC-3042 to help patients with cancer. This initial dose-escalation study demonstrated ...